Zota Health Care LImited — PPTs, 13-08-2026: Investor Presentation

**Business Performance:** Zota Health Care kicked off Q1FY27 with strong revenue of ₹173.60 Cr, largely driven by its Davaindia generic pharmacy chain, which contributed ₹143.42 Cr. Davaindia shows robust growth with ~58% CAGR since FY22 and high customer loyalty, boasting 80% repeat customers. However, the company reported a Q1FY27 loss of ₹43.94 Cr.

**Growth Drivers & Strategy:** The core strategy revolves around expanding Davaindia's network, now at 2,825 stores, offering 30-90% savings on generic medicines. Backward integration through a greater stake in Everyday Herbal Group enhances OTC product offerings. Management plans to moderate Q2FY27 expansion to optimize store performance before further growth.

**Recent Developments:** Key highlights include a successful ₹350 Cr QIP, the acquisition of Curexis, and an increased stake in Everyday Herbal. The company also launched "All day stores" and engaged prominent brand ambassadors like MS Dhoni, Suniel Shetty, and Akshay Kumar to boost national visibility.

**Key Financials & Outlook:** Q1FY27 revenue reached ₹173.60 Cr, with a Profit After Taxes loss of ₹43.94 Cr. Davaindia's FY26 Gross Merchandise Value was ₹457.06 Cr. Management is optimistic about long-term growth, focusing on strategic investments and improving store productivity.